Immunotherapy in Lung Cancer


The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

Latest News

Hossein Borghaei, MS, DO
IO Combos Yield OS Advantage Vs Chemo Alone in Stage IV PD-L1–Negative NSCLC

November 11th 2023

As treatments for patients with stage IV non–small cell lung cancer continue to evolve, patients with PD-L1–negative disease represent a unique cohort and chemotherapy/immunotherapy or immunotherapy doublet regimens appear to be effective.

Lung cancer: © -
Adjuvant Pembrolizumab Receives Positive CHMP Opinion for High-Risk NSCLC After Resection and Chemo

September 15th 2023

James Chih-Hsin Yang, MD, PhD, discusses the implications of the phase 3 KEYNOTE-789 trial and what directions investigators can examine in the future to help fill the unmet need for patients with TKI-resistant, EGFR-mutated metastatic non–small cell lung cancer.
Subgroup Observations From Missed KEYNOTE-789 Data in NSCLC Provide Insight for the Future

September 4th 2023

Data With TTFields Raise Questions Around the Future of Immunotherapy in Metastatic NSCLC

August 7th 2023

Solange Peters, MD, PhD
Further Research May Delineate Immunotherapy Resistance Mechanisms in Lung Cancer

August 2nd 2023

Video Series
Video Interviews

More News